|
PRPF39 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.42170000000586E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.47519999999612E-05 |
| Normal-vs-Stage2 |
1.5690499999943E-05 |
| Normal-vs-Stage3 |
1.5924999996475E-07 |
| Normal-vs-Stage4 |
7.826400E-04 |
| Stage1-vs-Stage2 |
1.488370E-01 |
| Stage1-vs-Stage3 |
4.783600E-02 |
| Stage1-vs-Stage4 |
3.284800E-01 |
| Stage2-vs-Stage3 |
9.998800E-01 |
| Stage2-vs-Stage4 |
8.736400E-01 |
| Stage3-vs-Stage4 |
8.604600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.67840000015107E-07 |
| Normal-vs-AfricanAmerican |
1.943490E-03 |
| Normal-vs-Asian |
8.887800E-02 |
| Caucasian-vs-AfricanAmerican |
9.352400E-01 |
| Caucasian-vs-Asian |
3.886000E-02 |
| AfricanAmerican-vs-Asian |
2.075800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.976980E-03 |
| Normal-vs-Female |
1.69370000024927E-07 |
| Male-vs-Female |
6.278000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.380990E-04 |
| Normal-vs-Age(41-60Yrs) |
1.84020000004725E-06 |
| Normal-vs-Age(61-80Yrs) |
1.70226999999246E-05 |
| Normal-vs-Age(81-100Yrs) |
2.34149999999156E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.766840E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.500770E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.185700E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.762800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.633550E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.774400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.72969999948592E-07 |
| Classical-VS-Follicular |
5.656000E-01 |
| Classical-VS-Other |
3.790200E-01 |
| Classical-VS-Normal |
1.038880E-04 |
| Tall-VS-Follicular |
1.016410E-03 |
| Tall-VS-Other |
1.101380E-01 |
| Tall-VS-Normal |
1.43830503063214E-11 |
| Follicular-VS-Other |
3.353400E-01 |
| Follicular-VS-Normal |
2.179500E-04 |
| Other-VS-Normal |
9.506800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.54229999999234E-06 |
| Normal-vs-N1 |
1.830840E-01 |
| N0-vs-N1 |
1.505790E-01 |
|
|
